ACOR - Nano-cap biotech Acorda surges 50% on drug launch

Neurology-focused nano-cap biotech Acorda Therapeutics (NASDAQ:ACOR) climbed over 50% on Thursday in reaction to the German launch of its inhalational Parkinson’s disease drug Inbrija in collaboration with Esteve Pharmaceuticals. Inbrija is indicated in Europe for intermittent treatment of episodic motor fluctuations in adults with Parkinson’s disease who have previously received a levodopa/dopa-decarboxylase inhibitor. According to an agreement between the two companies, Acorda (ACOR) is set to receive sales-based milestones and a double-digit percent of Inbrija selling price for its supplies. The company expects to begin receiving the revenue from 2Q 2022. Parkinson’s disease is the second commonest neurodegenerative disease in Germany affecting an estimated 20 people per 10,000 every year. In May, Acorda (ACOR) announced an agreement with South American pharma company, Biopas Laboratories to commercialize Inbrija in certain Latin American countries.

For further details see:

Nano-cap biotech Acorda surges 50% on drug launch